Who are the new users of antipsychotic medications?

Marisa Elena Domino, Marvin S Swartz
Author Information
  1. Marisa Elena Domino: Department of Health Policy and Administration, University of North Carolina, School of Public Health, Chapel Hill, NC 27599, USA. domino@unc.edu

Abstract

OBJECTIVE: This study examined changes in the prevalence of antipsychotic medication use and the characteristics of antipsychotic users in the U.S. population between 1996 and 2005.
METHODS: Data from the Medical Expenditure Panel Survey from 1996-1997 and 2004-2005 were used to examine the rate of first- and second-generation antipsychotic medication use and changes in the characteristics of users of all ages. Trends were examined in the level of use by antipsychotic users, both in terms of defined daily dose units and number of prescriptions.
RESULTS: The rate of antipsychotic use has increased substantially between 1996-1997 and 2004-2005, but the average dose measured both by defined daily dose units and number of prescriptions has remained constant. The rapid diffusion of antipsychotic medications did not occur among individuals with schizophrenia, but rather it included substantial growth among those with newer on-label conditions (such as bipolar disorder) and a high, constant rate of off-label use. Demographic, financial, and insurance characteristics of users have remained fairly constant, with few exceptions. The average age of antipsychotic users declined during the study period, because more children were using these medications in 2004-2005. However, the gender, racial, ethnic, and insurance composition of users has been fairly stable over time.
CONCLUSIONS: The rapid diffusion of second-generation antipsychotic medications was achieved by large increases in the rate of use in certain subpopulations, most notably youths. Increasing understanding about the marginal efficacy and side-effect risks of newer and more expensive antipsychotic agents, even when prescribed as indicated, suggests that the dramatic increase in use warrants careful attention.

References

  1. Health Aff (Millwood). 2006 May-Jun;25(3):635-46 [PMID: 16684726]
  2. N Engl J Med. 2005 Sep 22;353(12):1209-23 [PMID: 16172203]
  3. J Child Adolesc Psychopharmacol. 2007 Apr;17(2):195-203 [PMID: 17489714]
  4. Arch Gen Psychiatry. 2006 Jun;63(6):679-85 [PMID: 16754841]
  5. Expert Rev Pharmacoecon Outcomes Res. 2007 Apr;7(2):103-11 [PMID: 20528436]
  6. Milbank Q. 2005;83(2):271-98 [PMID: 15960772]
  7. J Clin Psychiatry. 2007 Feb;68(2):213-23 [PMID: 17335319]
  8. J Health Econ. 2005 Jan;24(1):1-31 [PMID: 15617786]
  9. Am J Psychiatry. 2006 Dec;163(12):2080-9 [PMID: 17151158]
  10. Control Clin Trials. 2004 Dec;25(6):598-612 [PMID: 15588746]
  11. J Am Acad Child Adolesc Psychiatry. 1999 May;38(5):537-45 [PMID: 10230185]
  12. J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):9-20 [PMID: 18174821]
  13. Am J Psychiatry. 2006 Dec;163(12):2047-56 [PMID: 17151153]
  14. Schizophr Bull. 2003;29(1):95-104 [PMID: 12908664]
  15. Ann Clin Psychiatry. 2006 Jul-Sep;18(3):183-94 [PMID: 16923657]
  16. Psychiatr Serv. 2005 Sep;56(9):1056-8 [PMID: 16148317]
  17. J Am Acad Child Adolesc Psychiatry. 2006 Mar;45(3):271-279 [PMID: 16540811]
  18. JAMA. 2005 Oct 19;294(15):1934-43 [PMID: 16234500]
  19. Psychiatry (Edgmont). 2007 May;4(5):21-3 [PMID: 20806026]
  20. Health Aff (Millwood). 2005 Jan-Feb;24(1):195-205 [PMID: 15647230]
  21. Am J Psychiatry. 2006 Feb;163(2):185-94 [PMID: 16449469]
  22. Schizophr Bull. 2003;29(1):15-31 [PMID: 12908658]
  23. Arch Dis Child. 2004 Dec;89(12):1131-2 [PMID: 15557050]
  24. N Engl J Med. 2005 Sep 22;353(12):1286-8 [PMID: 16172204]
  25. J Clin Psychiatry. 2006 Jun;67(6):972-82 [PMID: 16848658]
  26. Psychol Med. 2006 Nov;36(11):1535-40 [PMID: 16907994]
  27. Health Aff (Millwood). 2005 Jan-Jun;Suppl Web Exclusives:W5-133-W5-142 [PMID: 15797947]
  28. Arch Gen Psychiatry. 2006 Oct;63(10):1069-72 [PMID: 17015808]
  29. Arch Pediatr Adolesc Med. 2004 Aug;158(8):753-9 [PMID: 15289247]
  30. Arch Gen Psychiatry. 2006 Oct;63(10):1079-87 [PMID: 17015810]
  31. Br J Psychiatry. 2007 Jul;191:14-22 [PMID: 17602120]
  32. Arch Intern Med. 2006 May 8;166(9):1021-6 [PMID: 16682577]

Grants

  1. K01 MH065639/NIMH NIH HHS
  2. K01 MH065639-04/NIMH NIH HHS
  3. K01 MH 065639/NIMH NIH HHS
  4. N01 MH 90001/NIMH NIH HHS

MeSH Term

Adolescent
Adult
Antipsychotic Agents
Anxiety Disorders
Bipolar Disorder
Cost-Benefit Analysis
Drug Prescriptions
Female
Health Care Costs
Humans
Insurance, Health
Male
Medicaid
Middle Aged
Prevalence
Schizophrenia
United States

Chemicals

Antipsychotic Agents

Word Cloud

Created with Highcharts 10.0.0antipsychoticuseusersratecharacteristics2004-2005doseconstantmedicationsstudyexaminedchangesmedication1996-1997second-generationdefineddailyunitsnumberprescriptionsaverageremainedrapiddiffusionamongnewerinsurancefairlyOBJECTIVE:prevalenceUSpopulation19962005METHODS:DataMedicalExpenditurePanelSurveyusedexaminefirst-agesTrendsleveltermsRESULTS:increasedsubstantiallymeasuredoccurindividualsschizophreniaratherincludedsubstantialgrowthon-labelconditionsbipolardisorderhighoff-labelDemographicfinancialexceptionsagedeclinedperiodchildrenusingHowevergenderracialethniccompositionstabletimeCONCLUSIONS:achievedlargeincreasescertainsubpopulationsnotablyyouthsIncreasingunderstandingmarginalefficacyside-effectrisksexpensiveagentsevenprescribedindicatedsuggestsdramaticincreasewarrantscarefulattentionnewmedications?

Similar Articles

Cited By